Feb. 15, 2018
NewsScientific News

Caffeine as a biomarker for Parkinson's disease

Blood Levels of Caffeine and its Byproducts as Biomarkers

  • Caffeine is an organic molecule that, when consumed through e.g. coffee or tea, stimulates the central nervous system. Daily caffeine consumption has been shown to reduce the risk of developing Parkinson’s disease in men, and in women not taking hormone replacement therapy. Image: Alfonso Ianniello/Shutterstock.Caffeine is an organic molecule that, when consumed through e.g. coffee or tea, stimulates the central nervous system. Daily caffeine consumption has been shown to reduce the risk of developing Parkinson’s disease in men, and in women not taking hormone replacement therapy. Image: Alfonso Ianniello/Shutterstock.

Parkinson's disease is a degenerative disorder of the central nervous system, affecting the latter’s motor system — the part controlling bodily motion. Its symptoms include shaking, rigidity and difficulty with walking. There is evidence that daily caffeine consumption reduces the risk of developing Parkinson's. Now, a team of researchers led by Nobutaka Hattori from Juntendo University School of Medicine have studied how traces of caffeine in the blood, after drinking coffee, can be indicative of Parkinson's disease.

The researchers found that caffeine levels are significantly lower in patients with the disease; caffeine concentrations could therefore be used as an indicator of Parkinson's, particularly in its early stages.

The researchers studied a group of 139 people, both men and women, with and without Parkinson's disease. Each person drank between 0 and 5 cups of coffee per day (except for one participant who drank more than six). Then, they checked the participants’ blood serum for traces of caffeine and its 11 so-called downstream metabolites — small molecules produced during caffeine-induced metabolic processes in the human body.

The scientists found that the serum levels of caffeine and of almost all metabolites, including theophylline, theobromine and paraxanthine — caffeine’s main byproducts — were lower in patients with Parkinson's disease. Although the data obtained by Hattori’s team show that there is a clear relation between a person’s caffeine (metabolite) serum levels and having Parkinson's disease, there was no significant association between the severity of the disease and the concentration of any of the caffeine-related substances. Also, there was no significant difference in serum levels between male and female patients (males are known to suffer more often from Parkinson's disease).

The findings of Hattori and colleagues suggest that caffeine and caffeine metabolite levels in the blood can be, quoting the researchers, “early diagnostic biomarkers for the [Parkinson's] disease”; moreover, the results “further indicated the neuroprotective effects of caffeine”.

Original Publication:

Motoki Fujimaki, Shinji Saiki, Yuanzhe Li, Naoko Kaga, Hikari Taka, Taku Hatano, Kei-Ichi Ishikawa, Yutaka Oji, Akio Mori, Ayami Okuzumi, Takahiro Koinuma, Shin-Ichi Ueno, Yoko Imamichi, Takashi Ueno, Yoshiki Miura, Manabu Funayama, Nobutaka Hattori: Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease, Neurology (2018); DOI:

Register now!

The latest information directly via newsletter.

To prevent automated spam submissions leave this field empty.